Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 8/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917519 | 0.92 | CSNK2A1 (0.55) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL30573025 | 0.92 | CSNK2A1 (0.55) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL23932310 | 0.82 | CSNK2A1 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL827047 | 0.82 | GPR84 (0.54) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL2986160 | 0.79 | GPR84 (0.47) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL916811 | 0.75 | GPR84 (0.47) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL8648526 | 0.75 | ALOX15 (0.50) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL398920 | 0.75 | CSNK2A1 (0.60) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL1565699 | 0.75 | GPR84 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 | |
| SCHEMBL579164 | 0.75 | GPR84 (0.69) | CSNK2A1AHRCYP2A6NR4A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250206761-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025054431-A1 | BENZO-FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119301132-A | Halogenated indole macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-20150038484-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8889730-B2 | Indole and indazole compounds that activate AMPK | PFIZER INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | CSNK2A1 206/4885AHR 2749/4885CYP2A6 2013/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | CSNK2A1 411/4885AHR 3554/4885CYP2A6 1343/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CSNK2A1 371/4885AHR 1661/4885CYP2A6 2981/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CSNK2A1 371/4885AHR 1661/4885CYP2A6 2981/4885 |
| US-20250206761-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, HRAS | CSNK2A1 19/4885AHR 196/4885CYP2A6 1245/4885 |
| US-20150038484-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | CSNK2A1 406/4885AHR 169/4885CYP2A6 2160/4885 |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | CSNK2A1 406/4885AHR 169/4885CYP2A6 2160/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | CSNK2A1 371/4885AHR 1661/4885CYP2A6 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.